Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

References

• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321-30. doi:10.1038/nature21349. PMID:28102259
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97-111. doi:10.1038/nri.2016.107. PMID:27748397
   PubMed Web of Science ®Google Scholar
• Cheng WC, Ho PC. Metabolic tug-of-war in tumors results in diminished T cell antitumor immunity. Oncoimmunology. 2016;5:e1119355. doi:10.1080/2162402X.2015.1119355. PMID:27141402
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28:690-714. doi:10.1016/j.ccell.2015.10.012. PMID:26678337
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10. doi:10.1016/j.immuni.2013.07.012. PMID:23890059
   PubMed Web of Science ®Google Scholar
• Palucka AK, Coussens LM. The Basis of Oncoimmunology. Cell. 2016;164:1233-47. doi:10.1016/j.cell.2016.01.049. PMID:26967289
   PubMed Web of Science ®Google Scholar
• Hennequin A, Derangere V, Boidot R, Apetoh L, Vincent J, Orry D, Fraisse J, Causeret S, Martin F, Arnould L, et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology. 2016;5:e1054598. doi:10.1080/2162402X.2015.1054598. PMID:27057426
   PubMed Web of Science ®Google Scholar
• Sanchez-Martinez D, Azaceta G, Muntasell A, Aguilo N, Nunez D, Galvez EM, Naval J, Anel A, Palomera L, Vilches C, et al. Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. Oncoimmunology. 2015;4:e991613. doi:10.4161/2162402X.2014.991613. PMID:25949911
   PubMed Web of Science ®Google Scholar
• Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, Lopez-Diaz de Cerio A, Cabo M, Lopez-Botet M, Melero I. Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol. 2017;45:73-81. doi:10.1016/j.coi.2017.01.003. PMID:28236750
   PubMed Web of Science ®Google Scholar
• Muntasell A, Lopez-Botet M. Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future. Clin Cancer Res. 2016;22:1831-3. doi:10.1158/1078-0432.CCR-15-3168. PMID:26903071
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32:135-154. doi:10.1016/j.ccell.2017.06.009. PMID:28292442
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Bravo-San Pedro JM, Kroemer G, Galluzzi L, Gonzalez S. Involvement of autophagy in NK cell development and function. Autophagy. 2017;13:633-6. doi:10.1080/15548627.2016.1274486. PMID:28103115
   PubMed Web of Science ®Google Scholar
• Sanchez-Martinez D, Lanuza PM, Gomez N, Muntasell A, Cisneros E, Moraru M, Azaceta G, Anel A, Martinez-Lostao L, Villalba M, et al. Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. Front Immunol. 2016;7:454. doi:10.3389/fimmu.2016.00454. PMID:27833611
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486-99. doi:10.1038/nri3862. PMID:26205583
   PubMed Web of Science ®Google Scholar
• Geary SM, Lemke CD, Lubaroff DM, Salem AK. Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol. 2013;10:149-60. doi:10.1038/nrurol.2013.8. PMID:23399727
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15:388-400. doi:10.1038/nri3839. PMID:25998963
   PubMed Web of Science ®Google Scholar
• Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, Soon AL, Ricciardi-Castagnoli P. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. Oncoimmunology. 2016;5:e1085146. doi:10.1080/2162402X.2015.1085146. PMID:27141339
   PubMed Web of Science ®Google Scholar
• Baleeiro RB, Rietscher R, Diedrich A, Czaplewska JA, Lehr CM, Scherliess R, Hanefeld A, Gottschaldt M, Walden P. Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells. Oncoimmunology. 2015;4:e1047585. doi:10.1080/2162402X.2015.1047585. PMID:26985398
   PubMed Web of Science ®Google Scholar
• McDonnell AM, Joost Lesterhuis W, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BW. Restoration of defective cross-presentation in tumors by gemcitabine. Oncoimmunology. 2015;4:e1005501. doi:10.1080/2162402X.2015.1005501. PMID:26155402
   PubMed Web of Science ®Google Scholar
• Yatim N, Cullen S, Albert ML. Dying cells actively regulate adaptive immune responses. Nat Rev Immunol. 2017;17:262-75. doi:10.1038/nri.2017.9. PMID:28287107
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227-42. doi:10.1038/nri3405. PMID:23470321
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Zitvogel L, Kroemer G. Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. Cancer Immunol Res. 2016;4:895-902. doi:10.1158/2326-6066.CIR-16-0197. PMID:27803050
   PubMed Web of Science ®Google Scholar
• Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011;244:115-33. doi:10.1111/j.1600-065X.2011.01067.x. PMID:22017435
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9:271-85. doi:10.1038/nri2526. PMID:19319144
   PubMed Web of Science ®Google Scholar
• Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4:e1027469. doi:10.1080/2162402X.2015.1027469. PMID:26451310
   PubMed Web of Science ®Google Scholar
• Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35:51-60. doi:10.1016/j.it.2013.10.001. PMID:24210163
   PubMed Web of Science ®Google Scholar
• Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25:214-21. doi:10.1016/j.coi.2012.12.003. PMID:23298609
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16:7-19. doi:10.1038/nrc.2015.5. PMID:26694935
   PubMed Web of Science ®Google Scholar
• Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 2015;15:243-54. doi:10.1038/nri3799. PMID:25743219
   PubMed Web of Science ®Google Scholar
• Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol. 2004;4:190-8. doi:10.1038/nri1306. PMID:15039756
   PubMed Web of Science ®Google Scholar
• Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239-52. doi:10.1038/nri3174. PMID:22437937
   PubMed Web of Science ®Google Scholar
• Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology. 2015;4:e1016700. doi:10.1080/2162402X.2015.1016700. PMID:26140242
   PubMed Web of Science ®Google Scholar
• Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16:599-611. doi:10.1038/nri.2016.80. PMID:27526640
   PubMed Web of Science ®Google Scholar
• Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15:669-82. doi:10.1038/nri3902. PMID:26471778
   PubMed Web of Science ®Google Scholar
• Nirschl CJ, Suarez-Farinas M, Izar B, Prakadan S, Dannenfelser R, Tirosh I, Liu Y, Zhu Q, Devi KSP, Carroll SL, et al. IFNgamma-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. Cell. 2017;170:127-41.e15. doi:10.1016/j.cell.2017.06.016. PMID:28666115
   PubMed Web of Science ®Google Scholar
• Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell. 2017;169:750-65.e17. doi:10.1016/j.cell.2017.04.014. PMID:28475900
   PubMed Web of Science ®Google Scholar
• Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017;169:736-49.e18. doi:10.1016/j.cell.2017.04.016. PMID:28475899
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L. Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. Oncotarget. 2017;8:5686-91. PMID:27974686
   PubMed Web of Science ®Google Scholar
• Daniyan AF, Brentjens RJ. Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies. Nat Rev Clin Oncol. 2017;14:333-4. doi:10.1038/nrclinonc.2017.49. PMID:28397826
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472-508. doi:10.18632/oncotarget.2998. PMID:25537519
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64. doi:10.1038/nrc3239. PMID:22437870
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;in press. doi:10.1038/nrclinonc.2017.88. PMID:28653677
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275-87. doi:10.1038/nrc.2016.36. PMID:27079802
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205-14. doi:10.1016/j.cell.2015.03.030. PMID:25860605
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61. doi:10.1126/science.aaa8172. PMID:25838373
   PubMed Web of Science ®Google Scholar
• Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805-12. doi:10.1038/nrc3153. PMID:22020206
   PubMed Web of Science ®Google Scholar
• Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016;44:955-72. doi:10.1016/j.immuni.2016.05.002. PMID:27192563
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-13. doi:10.1126/science.aan6733. PMID:28596308
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Bloy N, Aranda F, Buque A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, et al. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology. 2016;5:e1214790. doi:10.1080/2162402X.2016.1214790. PMID:27757313
   PubMed Web of Science ®Google Scholar
• Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov. 2013;12:489-92. doi:10.1038/nrd4066. PMID:23812256
   PubMed Web of Science ®Google Scholar
• Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, et al. Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget. 2017;8:3197-205. PMID:27911273
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov. 2017;16:264-72. doi:10.1038/nrd.2016.233. PMID:28057932
   PubMed Web of Science ®Google Scholar
• Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16:121-6. doi:10.1038/nrc.2016.2. PMID:26822578
   PubMed Web of Science ®Google Scholar
• Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9:eaah3560. doi:10.1126/scitranslmed.aah3560. PMID:28251903
   PubMed Web of Science ®Google Scholar
• Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, et al. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017;77:839-50. doi:10.1158/0008-5472.CAN-15-3142. PMID:27821490
   PubMed Web of Science ®Google Scholar
• Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al. Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167:397-404.e9. doi:10.1016/j.cell.2016.08.069. PMID:27667683
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707-23. doi:10.1016/j.cell.2017.01.017. PMID:28187290
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165:35-44. doi:10.1016/j.cell.2016.02.065. PMID:26997480
   PubMed Web of Science ®Google Scholar
• De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature. 2016;539:443-7. doi:10.1038/nature20554. PMID:27828943
   PubMed Web of Science ®Google Scholar
• George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46:197-204. doi:10.1016/j.immuni.2017.02.001. PMID:28228279
   PubMed Web of Science ®Google Scholar
• Pol J, Buque A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2016;5:e1117740. doi:10.1080/2162402X.2015.1117740. PMID:27057469
   PubMed Web of Science ®Google Scholar
• Buque A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, et al. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology. 2016;5:e1149674. doi:10.1080/2162402X.2016.1149674. PMID:27471617
   PubMed Web of Science ®Google Scholar
• Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov. 2015;14:603-22. doi:10.1038/nrd4596. PMID:26228631
   PubMed Web of Science ®Google Scholar
• Hoos A. Development of immuno-oncology drugs – from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235-47. doi:10.1038/nrd.2015.35. PMID:26965203
   PubMed Web of Science ®Google Scholar
• Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566-81. doi:10.1038/nrc.2016.97. PMID:27550819
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642-62. doi:10.1038/nrd4663. PMID:26323545
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol. 2015;42:640-55. doi:10.1053/j.seminoncol.2015.05.014. PMID:26320067
   PubMed Web of Science ®Google Scholar
• Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res. 2013;19:1044-53. doi:10.1158/1078-0432.CCR-12-2065. PMID:23460535
   PubMed Web of Science ®Google Scholar
• Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e1008814. doi:10.1080/2162402X.2015.1008814. PMID:26137403
   PubMed Web of Science ®Google Scholar
• Fellermeier S, Beha N, Meyer JE, Ring S, Bader S, Kontermann RE, Muller D. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. Oncoimmunology. 2016;5:e1238540. doi:10.1080/2162402X.2016.1238540. PMID:27999756
   PubMed Web of Science ®Google Scholar
• Offringa R, Glennie MJ. Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework. Cancer Cell. 2015;28:273-5. doi:10.1016/j.ccell.2015.08.008. PMID:26373272
   PubMed Web of Science ®Google Scholar
• Wajant H. Therapeutic targeting of CD70 and CD27. Expert Opin Ther Targets. 2016;20:959-73. doi:10.1517/14728222.2016.1158812. PMID:26914723
   PubMed Web of Science ®Google Scholar
• Bullock TN. Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. Curr Opin Immunol. 2017;45:82-8. doi:10.1016/j.coi.2017.02.001. PMID:28319731
   PubMed Web of Science ®Google Scholar
• Wang X, Dong C. The CD70-CD27 axis, a new brake in the T helper 17 cell response. Immunity. 2013;38:1-3. doi:10.1016/j.immuni.2013.01.005. PMID:23352216
   PubMed Web of Science ®Google Scholar
• Leung J, Suh WK. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw. 2014;14:265-76. doi:10.4110/in.2014.14.6.265. PMID:25550693
   PubMedGoogle Scholar
• Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423-7. doi:10.1126/science.aaf0683. PMID:28280249
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428-33. doi:10.1126/science.aaf1292. PMID:28280247
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19:1035-43. doi:10.1158/1078-0432.CCR-12-2064. PMID:23460534
   PubMed Web of Science ®Google Scholar
• Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17:175-86. doi:10.1080/14737140.2017.1270208. PMID:27927088
   PubMed Web of Science ®Google Scholar
• Byrne KT, Vonderheide RH. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep. 2016;15:2719-32. doi:10.1016/j.celrep.2016.05.058. PMID:27292635
   PubMed Web of Science ®Google Scholar
• Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, et al. CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med. 2011;3:74ra22. doi:10.1126/scitranslmed.3001620.
   PubMed Web of Science ®Google Scholar
• van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol. 2004;173:6753-9. doi:10.4049/jimmunol.173.11.6753. PMID:15557168
   PubMed Web of Science ®Google Scholar
• Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2016;52:50-66. doi:10.1016/j.ejca.2015.08.021. PMID:26645943
   PubMed Web of Science ®Google Scholar
• Linch SN, McNamara MJ, Redmond WL. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol. 2015;5:34. doi:10.3389/fonc.2015.00034. PMID:25763356
   PubMed Web of Science ®Google Scholar
• Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004;4:420-31. doi:10.1038/nri1371. PMID:15173831
   PubMed Web of Science ®Google Scholar
• Souza-Fonseca-Guimaraes F, Blake SJ, Makkouk A, Chester C, Kohrt HE, Smyth MJ. Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. Oncoimmunology. 2016;5:e1192740. doi:10.1080/2162402X.2016.1192740. PMID:27622048
   PubMed Web of Science ®Google Scholar
• Makkouk A, Chester C, Kohrt HE. Rationale for anti-CD137 cancer immunotherapy. Eur J Cancer. 2016;54:112-9. doi:10.1016/j.ejca.2015.09.026. PMID:26751393
   PubMed Web of Science ®Google Scholar
• Chester C, Ambulkar S, Kohrt HE. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother. 2016;65:1243-8. doi:10.1007/s00262-016-1829-2. PMID:27034234
   PubMed Web of Science ®Google Scholar
• Alfaro C, Echeveste JI, Rodriguez-Ruiz ME, Solorzano JL, Perez-Gracia JL, Idoate MA, Lopez-Picazo JM, Sanchez-Paulete AR, Labiano S, Rouzaut A, et al. Functional expression of CD137 (4-1BB) on T helper follicular cells. Oncoimmunology. 2015;4:e1054597. doi:10.1080/2162402X.2015.1054597. PMID:26587331
   PubMed Web of Science ®Google Scholar
• Knee DA, Hewes B, Brogdon JL. Rationale for anti-GITR cancer immunotherapy. Eur J Cancer. 2016;67:1-10. doi:10.1016/j.ejca.2016.06.028. PMID:27591414
   PubMed Web of Science ®Google Scholar
• Zhu LX, Davoodi M, Srivastava MK, Kachroo P, Lee JM, St John M, Harris-White M, Huang M, Strieter RM, Dubinett S, et al. GITR agonist enhances vaccination responses in lung cancer. Oncoimmunology. 2015;4:e992237. doi:10.4161/2162402X.2014.992237. PMID:26137407
   PubMed Web of Science ®Google Scholar
• Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies–potential clinical applications for tumor immunotherapy. Curr Opin Investig Drugs. 2010;11:1378-86. PMID:21154120
   PubMed Web of Science ®Google Scholar
• Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010;22:326-32. doi:10.1016/j.coi.2010.01.001. PMID:20116985
   PubMed Web of Science ®Google Scholar
• Danielli R, Cutaia O, Fazio C, Bertocci E, Fonsatti E, Maio M, Calabro L. ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. Methods Mol Biol. 2016;1393:133-9. doi:10.1007/978-1-4939-3338-9_13. PMID:27033223
   PubMedGoogle Scholar
• Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014;211:715-25. doi:10.1084/jem.20130590. PMID:24687957
   PubMed Web of Science ®Google Scholar
• van Dodewaard-de Jong JM, Santegoets SJ, van de Ven PM, Versluis J, Verheul HM, de Gruijl TD, Gerritsen WR, van den Eertwegh AJ. Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. Oncoimmunology. 2016;5:e1105431. doi:10.1080/2162402X.2015.1105431. PMID:27141390
   PubMed Web of Science ®Google Scholar
• Maazi H, Patel N, Sankaranarayanan I, Suzuki Y, Rigas D, Soroosh P, Freeman GJ, Sharpe AH, Akbari O. ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. Immunity. 2015;42:538-51. doi:10.1016/j.immuni.2015.02.007. PMID:25769613
   PubMed Web of Science ®Google Scholar
• Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther. 2015;155:1-10. doi:10.1016/j.pharmthera.2015.07.007. PMID:26213107
   PubMed Web of Science ®Google Scholar
• Ruf M, Moch H, Schraml P. Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma. Oncoimmunology. 2015;4:e1049805. doi:10.1080/2162402X.2015.1049805. PMID:26587319
   PubMed Web of Science ®Google Scholar
• Kuka M, Munitic I, Giardino Torchia ML, Ashwell JD. CD70 is downregulated by interaction with CD27. J Immunol. 2013;191:2282-9. doi:10.4049/jimmunol.1300868. PMID:23913967
   PubMed Web of Science ®Google Scholar
• Coquet JM, Middendorp S, van der Horst G, Kind J, Veraar EA, Xiao Y, Jacobs H, Borst J. The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity. Immunity. 2013;38:53-65. doi:10.1016/j.immuni.2012.09.009. PMID:23159439
   PubMed Web of Science ®Google Scholar
• Munitic I, Kuka M, Allam A, Scoville JP, Ashwell JD. CD70 deficiency impairs effector CD8 T cell generation and viral clearance but is dispensable for the recall response to lymphocytic choriomeningitis virus. J Immunol. 2013;190:1169-79. doi:10.4049/jimmunol.1202353. PMID:23269247
   PubMed Web of Science ®Google Scholar
• Sato Y, Shimizu K, Shinga J, Hidaka M, Kawano F, Kakimi K, Yamasaki S, Asakura M, Fujii SI. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma. Oncoimmunology. 2015;4:e995541. doi:10.1080/2162402X.2014.995541. PMID:25949922
   PubMed Web of Science ®Google Scholar
• Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, Bianchi R, Bozza S, Volpi C, Salomon BL, Fioretti MC, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol. 2004;5:1134-42. doi:10.1038/ni1124. PMID:15467723
   PubMed Web of Science ®Google Scholar
• Bak SP, Barnkob MS, Bai A, Higham EM, Wittrup KD, Chen J. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J Immunol. 2012;189:1708-16. doi:10.4049/jimmunol.1201271. PMID:22798683
   PubMed Web of Science ®Google Scholar
• Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, et al. T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell. 2016;30:377-90. doi:10.1016/j.ccell.2016.08.004. PMID:27622331
   PubMed Web of Science ®Google Scholar
• Parrot T, Oger R, Benlalam H, Raingeard de la Bletiere D, Jouand N, Coutolleau A, Preisser L, Khammari A, Dreno B, Guardiola P, et al. CD40L confers helper functions to human intra-melanoma class-I-restricted CD4+CD8+ double positive T cells. Oncoimmunology. 2016;5:e1250991. doi:10.1080/2162402X.2016.1250991. PMID:28123891
   PubMed Web of Science ®Google Scholar
• Shin CA, Cho HW, Shin AR, Sohn HJ, Cho HI, Kim TG. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy. Oncotarget. 2016;7:46173-86. doi:10.18632/oncotarget.10068. PMID:27323820
   PubMed Web of Science ®Google Scholar
• Liljenfeldt L, Dieterich LC, Dimberg A, Mangsbo SM, Loskog AS. CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Cancer Gene Ther. 2014;21:95-102. doi:10.1038/cgt.2014.2. PMID:24481488
   PubMed Web of Science ®Google Scholar
• Gough MJ, Weinberg AD. OX40 (CD134) and OX40L. Adv Exp Med Biol. 2009;647:94-107. doi:10.1007/978-0-387-89520-8_6. PMID:19760068
   PubMed Web of Science ®Google Scholar
• Serebrovskaya EO, Yuzhakova DV, Ryumina AP, Druzhkova IN, Sharonov GV, Kotlobay AA, Zagaynova EV, Lukyanov SA, Shirmanova MV. Soluble OX40L favors tumor rejection in CT26 colon carcinoma model. Cytokine. 2016;84:10-6. doi:10.1016/j.cyto.2016.05.005. PMID:27203665
   PubMed Web of Science ®Google Scholar
• Godefroy E, Manches O, Dreno B, Hochman T, Roldoi:nitzky L, Labarriere N, Guilloux Y, Goldberg J, Jotereau F, Bhardwaj N. Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell. 2011;19:333-46. doi:10.1016/j.ccr.2011.01.037. PMID:21397857
   PubMed Web of Science ®Google Scholar
• Serghides L, Bukczynski J, Wen T, Wang C, Routy JP, Boulassel MR, Sekaly RP, Ostrowski M, Bernard NF, Watts TH. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol. 2005;175:6368-77. doi:10.4049/jimmunol.175.10.6368. PMID:16272289
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Yolcu ES, Dinc G, Sharma RK, Shirwan H. SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer. Oncoimmunology. 2016;5:e1064580. doi:10.1080/2162402X.2015.1064580. PMID:26942082
   PubMed Web of Science ®Google Scholar
• Rajendran S, Ho WT, Schwarz H. CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth. Oncoimmunology. 2016;5:e1160188. doi:10.1080/2162402X.2016.1160188. PMID:27471634
   PubMed Web of Science ®Google Scholar
• Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol. 1999;162:5003-10. PMID:10202049
   PubMed Web of Science ®Google Scholar
• Kang YJ, Kim SO, Shimada S, Otsuka M, Seit-Nebi A, Kwon BS, Watts TH, Han J. Cell surface 4-1BBL mediates sequential signaling pathways ‘downstream’ of TLR and is required for sustained TNF production in macrophages. Nat Immunol. 2007;8:601-9. doi:10.1038/ni1471. PMID:17496895
   PubMed Web of Science ®Google Scholar
• Nocentini G, Ronchetti S, Petrillo MG, Riccardi C. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. Br J Pharmacol. 2012;165:2089-99. doi:10.1111/j.1476-5381.2011.01753.x. PMID:22029729
   PubMed Web of Science ®Google Scholar
• Pedroza-Gonzalez A, Zhou G, Singh SP, Boor PP, Pan Q, Grunhagen D, de Jonge J, Tran TK, Verhoef C, JN IJ, et al. GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo. Oncoimmunology. 2015;4:e1051297. doi:10.1080/2162402X.2015.1051297. PMID:26587321
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luo Y, Qin SL, Mu YF, Qi Y, Yu MH, Zhong M. The clinical impact of ICOS signal in colorectal cancer patients. Oncoimmunology. 2016;5:e1141857. doi:10.1080/2162402X.2016.1141857. PMID:27467961
   PubMed Web of Science ®Google Scholar
• Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011;71:5445-54. doi:10.1158/0008-5472.CAN-11-1138. PMID:21708958
   PubMed Web of Science ®Google Scholar
• Liu D, Xu H, Shih C, Wan Z, Ma X, Ma W, Luo D, Qi H. T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction. Nature 2015;517:214-8. doi:10.1038/nature13803. PMID:25317561
   PubMed Web of Science ®Google Scholar
• Akbari O, Stock P, Meyer EH, Freeman GJ, Sharpe AH, Umetsu DT, DeKruyff RH. ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol 2008;180:5448-56. doi:10.4049/jimmunol.180.8.5448. PMID:18390727
   PubMed Web of Science ®Google Scholar
• He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 2013;191:4174-83. doi:10.4049/jimmunol.1300409. PMID:24026078
   PubMed Web of Science ®Google Scholar
• Akhmetzyanova I, Zelinskyy G, Littwitz-Salomon E, Malyshkina A, Dietze KK, Streeck H, Brandau S, Dittmer U. CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity. J Immunol 2016;196:484-92. doi:10.4049/jimmunol.1403039. PMID:26608920
   PubMed Web of Science ®Google Scholar
• Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008;205:825-39. doi:10.1084/jem.20071341. PMID:18362171
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-42. doi:10.1038/ni759. PMID:11812990
   PubMed Web of Science ®Google Scholar
• Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 2013;1:320-31. doi:10.1158/2326-6066.CIR-13-0086. PMID:24416730
   PubMed Web of Science ®Google Scholar
• Kim IK, Kim BS, Koh CH, Seok JW, Park JS, Shin KS, Bae EA, Lee GE, Jeon H, Cho J, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med. 2015;21:1010-7. doi:10.1038/nm.3922. PMID:26280119
   PubMed Web of Science ®Google Scholar
• Kim IK, Chung Y, Kang CY. GITR drives TH9-mediated antitumor immunity. Oncoimmunology. 2016;5:e1122862. doi:10.1080/2162402X.2015.1122862. PMID:27467921
   PubMed Web of Science ®Google Scholar
• Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, Urba WJ, Alvord G, Bunce C, Shields J. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 2000;164:2160-9. doi:10.4049/jimmunol.164.4.2160. PMID:10657670
   PubMed Web of Science ®Google Scholar
• Timperi E, Pacella I, Schinzari V, Focaccetti C, Sacco L, Farelli F, Caronna R, Del Bene G, Longo F, Ciardi A, et al. Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer. Oncoimmunology. 2016;5:e1175800. doi:10.1080/2162402X.2016.1175800. PMID:27622025
   PubMed Web of Science ®Google Scholar
• Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 2008;68:5206-15. doi:10.1158/0008-5472.CAN-07-6484. PMID:18593921
   PubMed Web of Science ®Google Scholar
• Xiao X, Shi X, Fan Y, Zhang X, Wu M, Lan P, Minze L, Fu YX, Ghobrial RM, Liu W, et al. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun. 2015;6:8266. doi:10.1038/ncomms9266. PMID:26365427
   PubMed Web of Science ®Google Scholar
• Kim YH, Shin SM, Choi BK, Oh HS, Kim CH, Lee SJ, Kim KH, Lee DG, Park SH, Kwon BS. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted. J Immunol. 2015;195:4721-9. doi:10.4049/jimmunol.1403076. PMID:26423152
   PubMed Web of Science ®Google Scholar
• Mahne AE, Mauze S, Joyce-Shaikh B, Xia J, Bowman EP, Beebe AM, Cua DJ, Jain R. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy. Cancer Res. 2017;77:1108-18. doi:10.1158/0008-5472.CAN-16-0797. PMID:28122327
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol. 2014;92:475-80. doi:10.1038/icb.2014.26. PMID:24732076
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210:1685-93. doi:10.1084/jem.20130573. PMID:23897982
   PubMed Web of Science ®Google Scholar
• Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 2011;19:101-13. doi:10.1016/j.ccr.2010.11.012. PMID:21251615
   PubMed Web of Science ®Google Scholar
• Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, Bullock TN. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother. 2010;33:769-79. doi:10.1097/CJI.0b013e3181ee238f. PMID:20842060
   PubMed Web of Science ®Google Scholar
• Weigelin B, Bolanos E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A, Quetglas JI, Wagena E, Sanchez-Paulete AR, et al. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc Natl Acad Sci U S A. 2015;112:7551-6. doi:10.1073/pnas.1506357112. PMID:26034288
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002;109:651-9. doi:10.1172/JCI0214184. PMID:11877473
   PubMed Web of Science ®Google Scholar
• Durham NM, Holoweckyj N, MacGill RS, McGlinchey K, Leow CC, Robbins SH. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory. J Immunother Cancer. 2017;5:47. doi:10.1186/s40425-017-0247-0. PMID:28649380
   PubMed Web of Science ®Google Scholar
• Franzese O, Palermo B, Di Donna C, Sperduti I, Ferraresi V, Stabile H, Gismondi A, Santoni A, Nistico P. Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncoimmunology. 2016;5:e1114203. doi:10.1080/2162402X.2015.1114203. PMID:27467927
   PubMed Web of Science ®Google Scholar
• Homet Moreno B, Mok S, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology. 2016;5:e1052212. doi:10.1080/2162402X.2015.1052212. PMID:27622011
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-6. doi:10.1126/science.1198443. PMID:21436454
   PubMed Web of Science ®Google Scholar
• Ellmark P, Mangsbo SM, Furebring C, Totterman TH, Norlen P. Kick-starting the cancer-immunity cycle by targeting CD40. Oncoimmunology. 2015;4:e1011484. doi:10.1080/2162402X.2015.1011484. PMID:26140231
   PubMed Web of Science ®Google Scholar
• Palazon A, Teijeira A, Martinez-Forero I, Hervas-Stubbs S, Roncal C, Penuelas I, Dubrot J, Morales-Kastresana A, Perez-Gracia JL, Ochoa MC, et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 2011;71:801-11. doi:10.1158/0008-5472.CAN-10-1733. PMID:21266358
   PubMed Web of Science ®Google Scholar
• Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood. 2010;116:3004-12. doi:10.1182/blood-2010-01-265280. PMID:20616215
   PubMed Web of Science ®Google Scholar
• Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcgammaR Engagement. Cancer Cell. 2016;29:820-31. doi:10.1016/j.ccell.2016.05.001. PMID:27265505
   PubMed Web of Science ®Google Scholar
• Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333:1030-4. doi:10.1126/science.1206954. PMID:21852502
   PubMed Web of Science ®Google Scholar
• Dubrovsky L, Brea EJ, Pankov D, Casey E, Dao T, Liu C, Scheinberg DA. Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity. Oncoimmunology. 2016;5:e1211221. doi:10.1080/2162402X.2016.1211221. PMID:27757306
   PubMed Web of Science ®Google Scholar
• Li F, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proc Natl Acad Sci U S A. 2013;110:19501-6. doi:10.1073/pnas.1319502110. PMID:24218606
   PubMed Web of Science ®Google Scholar
• Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Juttner M, Ehlert K, Kietz S, Muller I, Lode HN. Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. Oncoimmunology. 2016;5:e1235108. doi:10.1080/2162402X.2016.1235108. PMID:27999754
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunol Res. 2015;3:704-13. doi:10.1158/2326-6066.CIR-15-0120. PMID:26138698
   PubMed Web of Science ®Google Scholar
• White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell. 2015;27:138-48. doi:10.1016/j.ccell.2014.11.001. PMID:25500122
   PubMed Web of Science ®Google Scholar
• White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ. FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother. 2013;62:941-8. doi:10.1007/s00262-013-1398-6. PMID:23543215
   PubMed Web of Science ®Google Scholar
• White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol. 2011;187:1754-63. doi:10.4049/jimmunol.1101135. PMID:21742972
   PubMed Web of Science ®Google Scholar
• White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K, Williams EL, Booth SG, French RR, Potter EA, et al. Fcgamma receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. J Immunol. 2014;193:1828-35. doi:10.4049/jimmunol.1303204. PMID:25024386
   PubMed Web of Science ®Google Scholar
• Marshall E. Clinical medicine. Accident prompts a closer look at antibody trials. Science. 2006;312:172.
   PubMed Web of Science ®Google Scholar
• Hunig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol. 2012;12:317-8. doi:10.1038/nri3192-c2. PMID:22487653
   PubMed Web of Science ®Google Scholar
• Hansen S, Leslie RG. TGN1412: scrutinizing preclinical trials of antibody-based medicines. Nature. 2006;441:282. doi:10.1038/441282a. PMID:16710395
   PubMed Web of Science ®Google Scholar
• Schneider CK, Kalinke U, Lower J. TGN1412–a regulator's perspective. Nat Biotechnol. 2006;24:493-6. doi:10.1038/nbt0506-493. PMID:16680120
   PubMed Web of Science ®Google Scholar
• Wood AJ, Darbyshire J. Injury to research volunteers–the clinical-research nightmare. N Engl J Med. 2006;354:1869-71. doi:10.1056/NEJMp068082. PMID:16672696
   PubMed Web of Science ®Google Scholar
• Hunig T. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. Febs j. 2016;283:3325-34. doi:10.1111/febs.13754. PMID:27191544
   PubMed Web of Science ®Google Scholar
• Tyrsin D, Chuvpilo S, Matskevich A, Nemenov D, Romer PS, Tabares P, Hunig T. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:45-8. PMID:27586803
   PubMed Web of Science ®Google Scholar
• Dyer O. Experimental drug that injured UK volunteers resumes in human trials. Bmj. 2015;350:h1831. doi:10.1136/bmj.h1831. PMID:25838401
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Bloy N, Buque A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, et al. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology. 2016;5:e1115942. doi:10.1080/2162402X.2015.1115942. PMID:27057468
   PubMed Web of Science ®Google Scholar
• Bloy N, Buque A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautes-Fridman C, Fucikova J, Galon J, Spisek R, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4:e1026531. doi:10.1080/2162402X.2015.1026531. PMID:26155408
   PubMed Web of Science ®Google Scholar
• Zippelius A, Schreiner J, Herzig P, Muller P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015;3:236-44. doi:10.1158/2326-6066.CIR-14-0226. PMID:25623164
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ. Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. Cancer Res. 2016;76:6266-77. doi:10.1158/0008-5472.CAN-16-2141. PMID:27634762
   PubMed Web of Science ®Google Scholar
• Buchan S, Manzo T, Flutter B, Rogel A, Edwards N, Zhang L, Sivakumaran S, Ghorashian S, Carpenter B, Bennett C, et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Immunol. 2015;194:125-33. doi:10.4049/jimmunol.1401644. PMID:25404365
   PubMed Web of Science ®Google Scholar
• Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI, et al. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov. 2016;6:71-9. doi:10.1158/2159-8290.CD-15-0510. PMID:26493961
   PubMed Web of Science ®Google Scholar
• McKee SJ, Doff BL, Soon MS, Mattarollo SR. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma. Cancer Immunol Res. 2017;5:191-7. doi:10.1158/2326-6066.CIR-16-0249. PMID:28115358
   PubMed Web of Science ®Google Scholar
• Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463-82. doi:10.1038/nrclinonc.2017.43. PMID:28374786
   PubMed Web of Science ®Google Scholar
• Ryan JM, Wasser JS, Adler AJ, Vella AT. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther. 2016;16:655-74. doi:10.1517/14712598.2016.1152256. PMID:26855028
   PubMed Web of Science ®Google Scholar
• Mangsbo SM, Broos S, Fletcher E, Veitonmaki N, Furebring C, Dahlen E, Norlen P, Lindstedt M, Totterman TH, Ellmark P. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res. 2015;21:1115-26. doi:10.1158/1078-0432.CCR-14-0913. PMID:25316820
   PubMed Web of Science ®Google Scholar
• Dronca RS, Dong H. Immunomodulatory antibody therapy of cancer: the closer, the better. Clin Cancer Res. 2015;21:944-6. doi:10.1158/1078-0432.CCR-14-2111. PMID:25351746
   PubMed Web of Science ®Google Scholar
• Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S. Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology. 2015;4:e1001236. doi:10.1080/2162402X.2014.1001236. PMID:26155388
   PubMed Web of Science ®Google Scholar
• Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines–hope or hype? Nat Rev Immunol. 2014;14:705-11. doi:10.1038/nri3727. PMID:25190285
   PubMed Web of Science ®Google Scholar
• Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509-24. doi:10.1038/nrclinonc.2014.111. PMID:25001465
   PubMed Web of Science ®Google Scholar
• Mullard A. The cancer vaccine resurgence. Nat Rev Drug Discov. 2016;15:663-5. doi:10.1038/nrd.2016.201. PMID:27681782
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16:219-33. doi:10.1038/nrc.2016.16. PMID:26965076
   PubMed Web of Science ®Google Scholar
• Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson JH. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017;13:363-74. doi:10.1038/nrneurol.2017.64. PMID:28497804
   PubMed Web of Science ®Google Scholar
• Amato RJ. Heat-shock protein-peptide complex-96 for the treatment of cancer. Expert Opin Biol Ther. 2007;7:1267-73. doi:10.1517/14712598.7.8.1267. PMID:17696824
   PubMed Web of Science ®Google Scholar
• Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spisek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 2011;71:4821-33. doi:10.1158/0008-5472.CAN-11-0950. PMID:21602432
   PubMed Web of Science ®Google Scholar
• Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109:4839-45. doi:10.1182/blood-2006-10-054221. PMID:17299090
   PubMed Web of Science ®Google Scholar
• Spisek R, Dhodapkar MV. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle. 2007;6:1962-5. doi:10.4161/cc.6.16.4601. PMID:17721082
   PubMed Web of Science ®Google Scholar
• Wu BX, Hong F, Zhang Y, Ansa-Addo E, Li Z. GRP94/gp96 in Cancer: Biology, Structure, Immunology, and Drug Development. Adv Cancer Res. 2016;129:165-90. doi:10.1016/bs.acr.2015.09.001. PMID:26916005
   PubMed Web of Science ®Google Scholar
• Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination. Cancer Immunol Res. 2016;4:766-78. doi:10.1158/2326-6066.CIR-15-0228. PMID:27364122
   PubMed Web of Science ®Google Scholar
• Liu Z, Hao X, Zhang Y, Zhang J, Carey CD, Falo LD, Jr., Storkus WJ, You Z. Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist alpha-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity. Oncoimmunology. 2017;6:e1315487. doi:10.1080/2162402X.2017.1315487. PMID:28680744
   PubMed Web of Science ®Google Scholar
• Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Gilboa E. Reducing toxicity of 4-1BB costimulation: targeting 4-1BB ligands to the tumor stroma with bi-specific aptamer conjugates. Oncoimmunology. 2015;4:e970918. doi:10.4161/21624011.2014.970918. PMID:25949891
   PubMed Web of Science ®Google Scholar
• Yelamos J, Galindo M, Navarro J, Albanell J, Rovira A, Rojo F, Oliver J. Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. Oncoimmunology. 2016;5:e1065370. doi:10.1080/2162402X.2015.1065370. PMID:26942084
   PubMed Web of Science ®Google Scholar
• Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611-25. doi:10.1038/nrm.2016.87. PMID:27461391
   PubMed Web of Science ®Google Scholar
• Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403. doi:10.1038/nrd.2015.17. PMID:26775688
   PubMed Web of Science ®Google Scholar
• Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409-25. doi:10.1038/nrc3958. PMID:26105538
   PubMed Web of Science ®Google Scholar
• Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, Garcia-Martinez E, Rudqvist NP, Formenti SC, Demaria S. Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol. 2017;8:229. doi:10.3389/fimmu.2017.00229. PMID:28348554
   PubMed Web of Science ®Google Scholar
• Demaria S, Formenti SC. Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? J Immunother Cancer. 2016;4:29. doi:10.1186/s40425-016-0133-1. PMID:27190630
   PubMed Web of Science ®Google Scholar
• Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795-803. PMID:26095785
   PubMed Web of Science ®Google Scholar
• Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol. 2015;25:28-33. PMID:25481263
   PubMed Web of Science ®Google Scholar
• Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP, Brenneman R, Umland O, Yagita H, Gilboa E, et al. Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation. Cancer Res. 2017;77:1310-21. PMID:28082399
   PubMed Web of Science ®Google Scholar
• Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res. 2014;2:867-77. PMID:24938283
   PubMed Web of Science ®Google Scholar
• Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE, 3rd, et al. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017;35:2028-36. PMID:28463630
   PubMed Web of Science ®Google Scholar
• Sanborn RE, Pishvain MJ, Callahan MK, Rizvi N, Kluger H, Yellin M, Rawls T, Vitale L, Halim A, Davis T, et al. Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events. Cancer Research. 2016;76:CT023.
   Web of Science ®Google Scholar
• Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, et al. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015;56:2569-78. PMID:25651427
   PubMed Web of Science ®Google Scholar
• Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015;26:2483-90. PMID:26386124
   PubMed Web of Science ®Google Scholar
• Bajor DL, Mick R, Riese MJ, Richman LP, Xu X, Torigian DA, Stelekati E, Sweeney M, Sullivan B, Schuchter LM, et al. Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma. Cancer Research. 2015;75:CT137.
   Web of Science ®Google Scholar
• Johnson P, Challis R, Chowdhury F, Gao Y, Harvey M, Geldart T, Kerr P, Chan C, Smith A, Steven N, et al. Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin Cancer Res. 2015;21:1321-8. doi:10.1158/1078-0432.CCR-14-2355. PMID:25589626
   PubMed Web of Science ®Google Scholar
• Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, et al. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res. 2017;23:1929-36. doi:10.1158/1078-0432.CCR-16-1272. PMID:27756788
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco D, Di Gravio D, Huang B, Gambhire D, Chen Y, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017;in press. doi:10.1158/1078-0432.CCR-17-1243. PMID:28634283
   PubMed Web of Science ®Google Scholar
• Gopal AK, Bartlett NL, Levy R, Houot R, Smith SD, Segal NH, Thall AD, Mugundu G, Huang B, Davis C, et al. A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. Journal of Clinical Oncology. 2015;33:3004.
   Google Scholar
• Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso P, Rasmussen E, Juan G, Upreti VV, Ngarmchamnanrith G, Schöffski P. Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors. J Clin Oncol. 2017;35:2521.
   Web of Science ®Google Scholar
• Koon HB, Shepard DR, Merghoub T, Schaer DA, Sirard CA, Wolchok JD. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. Journal of Clinical Oncology. 2016;34:3017.
   Web of Science ®Google Scholar
• Siu LL, Steeghs N, Meniawy T, Joerger M, Spratlin JL, Rottey S, Nagrial A, Cooper A, Meier R, Guan X, et al. Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors. Journal of Clinical Oncology. 2017;35:104.
   Google Scholar
• Burris HA, Callahan MK, Tolcher AW, Kummar S, Falchook GS, Pachynski RK, Tykodi SS, Gibney GT, Seiwert TY, Gainor JF, et al. Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC. J Clin Oncol. 2017;35:3033.
   Web of Science ®Google Scholar
• El-Khoueiry AB, Hamid O, Thompson JA, Ros W, Eskens F, Doi T, Hu-Lieskovan S, Chou J, Liao K, Ganguly BJ, et al. The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600). Journal of Clinical Oncology. 2017;35:3027.
   Google Scholar
• Infante JR, Hansen AR, Pishvaian MJ, Chow LQM, McArthur GA, Bauer TM, Liu SV, Sandhu SK, Tsai FY-C, Kim J, et al. A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. Journal of Clinical Oncology. 2016;34:101.
   Web of Science ®Google Scholar
• Glisson BS, Leidner R, Ferris RL, Powderly J, Rizvi N, Norton JD, Burton J, Lanasa MC, Patel SP. Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors. Annals of Oncology. 2016;27:1052PD. doi:10.1093/annonc/mdw378.07.
   Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016;44:1069-78. doi:10.1016/j.immuni.2016.04.023. PMID:27192570
   PubMed Web of Science ®Google Scholar
• Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:26. doi:10.1186/s12929-017-0329-9. PMID:28376884
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015;4:e1058037. doi:10.1080/2162402X.2015.1058037. PMID:26140249
   PubMed Web of Science ®Google Scholar
• Yu GT, Bu LL, Zhao YY, Mao L, Deng WW, Wu TF, Zhang WF, Sun ZJ. CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma. Oncoimmunology. 2016;5:e1151594. doi:10.1080/2162402X.2016.1151594. PMID:27471622
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e985940. doi:10.4161/2162402X.2014.985940. PMID:25949870
   PubMed Web of Science ®Google Scholar
• Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautes-Fridman C, Fucikova J, Galon J, Spisek R, et al. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4:e1008866. doi:10.1080/2162402X.2015.1008866. PMID:26137404
   PubMed Web of Science ®Google Scholar
• Hanoteau A, Moser M. Chemotherapy and immunotherapy: A close interplay to fight cancer? Oncoimmunology. 2016;5:e1190061. doi:10.1080/2162402X.2016.1190061. PMID:27622046
   PubMed Web of Science ®Google Scholar
• Varlilumab Is Safe and Active in Patients with Advanced Solid Tumors. Cancer Discov. 2017;7:OF9. doi:10.1158/2159-8290.CD-RW2017-089.
   Web of Science ®Google Scholar
• Sanmamed MF, Rodriguez I, Schalper KA, Onate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Perez-Gracia JL, Martin-Algarra S, et al. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rgammanull Immunodeficient Mice. Cancer Res. 2015;75:3466-78. doi:10.1158/0008-5472.CAN-14-3510. PMID:26113085
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-33. doi:10.1056/NEJMoa1302369. PMID:23724867
   PubMed Web of Science ®Google Scholar
• Ruter J, Antonia SJ, Burris HA, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010;10:983-93. doi:10.4161/cbt.10.10.13251. PMID:20855968
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876-83. doi:10.1200/JCO.2006.08.3311. PMID:17327609
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabro L, Chiou M, Tap W, Chmielowski B, et al. CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother. 2010;33:810-6. doi:10.1097/CJI.0b013e3181ee73a7. PMID:20842056
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Mick R, Ruter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 2009;7:93. doi:10.1186/1479-5876-7-93. PMID:19906293
   PubMed Web of Science ®Google Scholar
• Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016; 2016:567-72. PMID:27913530
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119-22. doi:10.1097/PPO.0000000000000035. PMID:24667956
   PubMed Web of Science ®Google Scholar
• Walker M, Makropoulos D, Achuthanandam R, Bugelski PJ. Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome. Curr Opin Drug Discov Devel. 2010;13:124-35. PMID:20047153
   PubMedGoogle Scholar
• Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P, Intensive Care in H, Oncological Patients Collaborative G. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21:89. doi:10.1186/s13054-017-1678-1. PMID:28407743
   PubMed Web of Science ®Google Scholar
• Remer M, White A, Glennie M, Al-Shamkhani A, Johnson P. The Use of Anti-CD40 mAb in Cancer. Curr Top Microbiol Immunol. 2017;405:165-207. PMID:25651948
   PubMed Web of Science ®Google Scholar
• Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol. 2012;12:749-61. doi:10.1038/nri3307. PMID:23080391
   PubMed Web of Science ®Google Scholar
• Laidlaw BJ, Craft JE, Kaech SM. The multifaceted role of CD4(+) T cells in CD8(+) T cell memory. Nat Rev Immunol. 2016;16:102-11. doi:10.1038/nri.2015.10. PMID:26781939
   PubMed Web of Science ®Google Scholar
• Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. Nat Rev Immunol. 2016;16:90-101. doi:10.1038/nri.2015.1. PMID:26688349
   PubMed Web of Science ®Google Scholar
• Ramakrishna V, Sundarapandiyan K, Zhao B, Bylesjo M, Marsh HC, Keler T. Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. J Immunother Cancer. 2015;3:37. doi:10.1186/s40425-015-0080-2. PMID:26500773
   PubMed Web of Science ®Google Scholar
• Ferte C, Marabelle A. iRECIST: A clarification of tumour response assessment in the immunotherapy era. Eur J Cancer. 2017;77:165-7. doi:10.1016/j.ejca.2017.02.015. PMID:28385325
   PubMed Web of Science ®Google Scholar
• Le Lay J, Jarraya H, Lebellec L, Penel N. IrRECIST and iRECIST: the devil is in the details. Ann Oncol. 2017. PMID:28383646
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143-e52. doi:10.1016/S1470-2045(17)30074-8. PMID:28271869
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405-14. doi:10.1038/nri3845. PMID:26027717
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. doi:10.1038/ncomms15618. PMID:28598415
   PubMed Web of Science ®Google Scholar
• Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, et al. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol. 2015;6:402. doi:10.3389/fimmu.2015.00402. PMID:26300886
   PubMed Web of Science ®Google Scholar
• de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007;67:6253-62. doi:10.1158/0008-5472.CAN-07-0538. PMID:17616683
   PubMed Web of Science ®Google Scholar
• Saxon JA, Sherrill TP, Polosukhin VV, Sai J, Zaynagetdinov R, McLoed AG, Gulleman PM, Barham W, Cheng DS, Hunt RP, et al. Epithelial NF-kappaB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment. Oncoimmunology. 2016;5:e1168549. doi:10.1080/2162402X.2016.1168549. PMID:27471643
   PubMed Web of Science ®Google Scholar
• Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer. 2014;2:10. doi:10.1186/2051-1426-2-10. PMID:24883189
   PubMedGoogle Scholar
• Yamazaki N, Kiyohara Y, Uhara H, Iizuka H, Uehara J, Otsuka F, Fujisawa Y, Takenouchi T, Isei T, Iwatsuki K, et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Sci. 2017;108:1022-31. doi:10.1111/cas.13226. PMID:28266140
   PubMed Web of Science ®Google Scholar
• Lever M, Maini PK, van der Merwe PA, Dushek O. Phenotypic models of T cell activation. Nat Rev Immunol. 2014;14:619-29. doi:10.1038/nri3728. PMID:25145757
   PubMed Web of Science ®Google Scholar
• Li MO, Rudensky AY. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol. 2016;16:220-33. doi:10.1038/nri.2016.26. PMID:27026074
   PubMed Web of Science ®Google Scholar
• Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol. 2014;14:435-46. doi:10.1038/nri3701. PMID:24962260
   PubMed Web of Science ®Google Scholar
• Flemming A. Cancer: Tumour-specific ablation of Treg cells induces anticancer response. Nat Rev Drug Discov. 2016;15:676-7. doi:10.1038/nrd.2016.198.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306. doi:10.1038/nrc3245. PMID:22419253
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;in press. doi:10.1038/nrclinonc.2017.101. PMID:28741618
   PubMed Web of Science ®Google Scholar
• Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 2017;in press. doi:10.1038/nri.2017.75. PMID: 28757603
   PubMedGoogle Scholar
• Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, Banissi C, Galluzzi L, Kroemer G, Tartour E. Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron. 2013;6:147-57. doi:10.1007/s12307-012-0122-y. PMID:23104434
   PubMedGoogle Scholar
• Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs. 2009;10:579-87. PMID:19513947
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:4371-7. doi:10.1200/JCO.2008.21.3017. PMID:19636010
   PubMed Web of Science ®Google Scholar
• Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51:228-35. doi:10.3109/10428190903440946. PMID:20038235
   PubMed Web of Science ®Google Scholar
• Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010;95:845-8. doi:10.3324/haematol.2009.008003. PMID:20133895
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:277-83. doi:10.3109/10428194.2012.710328. PMID:22775314
   PubMed Web of Science ®Google Scholar
• Binder DC, Davis AA, Wainwright DA. Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology. 2016;5:e1082027. doi:10.1080/2162402X.2015.1082027. PMID:27057463
   PubMed Web of Science ®Google Scholar
• Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, et al. Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. Oncoimmunology. 2016;5:e1186323. doi:10.1080/2162402X.2016.1186323. PMID:27622041
   PubMed Web of Science ®Google Scholar
• Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2:e000213. doi:10.1136/esmoopen-2017-000213. PMID:28761757
   PubMed Web of Science ®Google Scholar
• Meng X, Liu Y, Zhang J, Teng F, Xing L, Yu J. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. Cancer Lett. 2017;405:29-37. doi:10.1016/j.canlet.2017.06.033. PMID:28688973
   PubMed Web of Science ®Google Scholar
• Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14:203-20. doi:10.1038/nrclinonc.2016.168. PMID:27805626
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561-84. doi:10.1038/nrd4591. PMID:26228759
   PubMed Web of Science ®Google Scholar
• Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17:286-301. doi:10.1038/nrc.2017.17. PMID:28338065
   PubMed Web of Science ®Google Scholar
• Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016;2:286-94. doi:10.1016/j.trecan.2016.05.002. PMID:27774519
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Formenti SC, Demaria S. Towards precision radiotherapy for use with immune checkpoint blockers. Clin Cancer Res. 2017. doi:10.1158/1078-0432.CCR-16-0037.
   PubMedGoogle Scholar
• Galluzzi L, Bravo-San Pedro JM, Demaria S, Formenti SC, Kroemer G. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Nat Rev Clin Oncol. 2017;14:247-58. doi:10.1038/nrclinonc.2016.183. PMID:27845767
   PubMed Web of Science ®Google Scholar
• Melero I, Berraondo P, Rodriguez-Ruiz ME, Perez-Gracia JL. Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. Cancer Discov. 2016;6:1312-4. doi:10.1158/2159-8290.CD-16-1109. PMID:27920139
   PubMed Web of Science ®Google Scholar
• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12-23. doi:10.1038/nrclinonc.2013.197. PMID:24217204
   PubMed Web of Science ®Google Scholar
• Zhang F, Yang J, Li H, Liu M, Zhang J, Zhao L, Wang L, LingHu R, Feng F, Gao X, et al. Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization. Oncoimmunology. 2016;5:e1143995. doi:10.1080/2162402X.2016.1143995. PMID:27467962
   PubMed Web of Science ®Google Scholar
• Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13:496-511. doi:10.1038/nrneph.2017.82. PMID:28691713
   PubMed Web of Science ®Google Scholar
• Draghiciu O, Boerma A, Hoogeboom BN, Nijman HW, Daemen T. A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology. 2015;4:e1029699. doi:10.1080/2162402X.2015.1029699. PMID:26451295
   PubMed Web of Science ®Google Scholar
• Blick C, Ritchie AWS, Eisen T, Stewart GD. Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials. Nat Rev Urol. 2017;in press. doi:10.1038/nrurol.2017.123. PMID:28762388
   PubMedGoogle Scholar
• Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14:57-66. doi:10.1038/nrclinonc.2016.96. PMID:27377132
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12:829-46. doi:10.1038/nrd4145. PMID:24113830
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Buque A, Eggermont A, Cremer I, Sautes-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology. 2015;4:e974411. doi:10.4161/2162402X.2014.974411. PMID:26137405
   PubMed Web of Science ®Google Scholar
• Le Noci V, Sommariva M, Tortoreto M, Zaffaroni N, Campiglio M, Tagliabue E, Balsari A, Sfondrini L. Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. Oncoimmunology. 2016;5:e1234571. doi:10.1080/2162402X.2016.1234571. PMID:27999750
   PubMed Web of Science ®Google Scholar
• Iribarren K, Bloy N, Buque A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, et al. Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology. 2016;5:e1088631. doi:10.1080/2162402X.2015.1088631. PMID:27141345
   PubMed Web of Science ®Google Scholar
• Junt T, Barchet W. Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol. 2015;15:529-44. doi:10.1038/nri3875. PMID:26292638
   PubMed Web of Science ®Google Scholar
• Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9:293-307. doi:10.1038/nrd3203. PMID:20380038
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi:10.1038/nrdp.2017.9. PMID:28276433
   PubMed Web of Science ®Google Scholar
• Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. Oncoimmunology. 2016;5:e1188243. doi:10.1080/2162402X.2016.1188243. PMID:27622042
   PubMed Web of Science ®Google Scholar
• Baker LC, Boult JK, Thomas M, Koehler A, Nayak T, Tessier J, Ooi CH, Birzele F, Belousov A, Zajac M, et al. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling. Br J Cancer. 2016;115:691-702. doi:10.1038/bjc.2016.236. PMID:27529514
   PubMed Web of Science ®Google Scholar
• Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs. 2016;8:1010-20. doi:10.1080/19420862.2016.1197457. PMID:27285945
   PubMed Web of Science ®Google Scholar
• Tampellini M, Sonetto C, Scagliotti GV. Novel anti-angiogenic therapeutic strategies in colorectal cancer. Expert Opin Investig Drugs. 2016;25:507-20. doi:10.1517/13543784.2016.1161754. PMID:26938715
   PubMed Web of Science ®Google Scholar
• Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016;5:e1090075. doi:10.1080/2162402X.2015.1090075. PMID:27141347
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Mogamulizumab: 2 birds, 1 stone. Blood. 2015;125:1847-8. doi:10.1182/blood-2015-02-625251. PMID:25792728
   PubMed Web of Science ®Google Scholar
• Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Muller C, Jegg AM, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16:949-56. doi:10.1016/S1470-2045(15)00132-1. PMID:26179200
   PubMed Web of Science ®Google Scholar
• Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5:53. doi:10.1186/s40425-017-0257-y.
   PubMed Web of Science ®Google Scholar
• Casbon AJ, Lohela M, Werb Z. Delineating CSF-1-dependent regulation of myeloid cell diversity in tumors. Oncoimmunology. 2015;4:e1008871. doi:10.1080/2162402X.2015.1008871. PMID:26155427
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9:327-37. doi:10.1038/nrclinonc.2012.59. PMID:22473096
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Levy R. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res. 2013;19:5261-3. doi:10.1158/1078-0432.CCR-13-1923. PMID:23965900
   PubMed Web of Science ®Google Scholar
• Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res. 2013;19:5381-9. doi:10.1158/1078-0432.CCR-12-0781. PMID:23788581
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology. 2014;3:e27297. doi:10.4161/onci.27297. PMID:24701370
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 2012;1:28-37. doi:10.4161/onci.1.1.17938. PMID:22720209
   PubMed Web of Science ®Google Scholar
• Shi Y, Du L, Lin L, Wang Y. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16:35-52. doi:10.1038/nrd.2016.193. PMID:27811929
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399-416. doi:10.1038/nrclinonc.2016.217. PMID:28117416
   PubMed Web of Science ®Google Scholar
• Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16:447-62. doi:10.1038/nrc.2016.54. PMID:27339708
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: A beneficial liaison? Nat Rev Clin Oncol. 2017;14:365-79. doi:10.1038/nrclinonc.2016.211. PMID:28094262
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13:143-58. doi:10.1038/nrclinonc.2015.209. PMID:26598942
   PubMed Web of Science ®Google Scholar
• Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:394. doi:10.1038/nrclinonc.2016.65. PMID:27118494
   PubMed Web of Science ®Google Scholar